Re-engineering CD4 T- Cells into Lineage Specifiic, Pluripotent Stem Cells (Tscm)

Contracts Guide

Disclose Your Invention
MTA/CDA Assistance
COVID-19 Related Agreements
Main Campus Research
Office of Sponsored Research
Education Links

Connect with Industry

Technologies for Licensing
Industry Collaboration Opportunities
Research and Clinical Trials

Categories: “Other Disorders

Reference #: 2020-030

OTC Contact: Ruchika Nijhara, PhD, MBA, CLP; Office: (202) 687-3721 (Directory Information | Send a Message)


The present invention introduces a method of re-engineering CD4 T-cells to induce stem cell like memory (Tscm) functions therein. The proposed method uses MEK 1/2 inhibitors to produce CD4 memory cells with stem cell properties. The MEK 1/2 inhibition allows naïve CD4 T-cells to become amenable to lineage specific conditioning, leading to the generation of specific effectors cells upon antigenic stimulation. Thus, the invention provides a means of generating disease specific Tscm cells, with properties including; self-renewability, robust antigen specific responses and cytokine sensitive differentiation into CD4 subpopulations.


T-cell therapy is a fast-growing area of interest in treatment approaches to cancer and other diseases. The current state of the art utilizes variations of in-vitro strategies to generate therapeutic T-cells, ultimately requiring the re-infusion of modified T-cells. These approaches invariably require a large number of T-cells to prove efficacious, and these cells undergo exhaustion and apoptosis.

Georgetown researchers herein advance an approach focused on re-engineering such cells into Tscm. This novel approach establishes significantly effective tool for the generation of high-fidelity therapeutic T cells that are robust and patient specific. Furthermore, this proposal induces pluripotency, granting T-cells the ability to differentiate into different CD4 subtypes that can be utilized in a wide range of pathological conditions.




Have generated Tscm CD4 cells and tested their anti-tumor potential in pre-clinical models. The methods for the generation of these cells and their application have been validated.


Patent application has been filed.


Samir Khleif
Vivek Verma